Original story
Internet News -2.2.2001
Great strides in cure for osteoporosis
A research team at the Swedish Karolina Institute has made a breakthrough in the treatment of osteoporosis, one of the most common ailments facing the elderly, particularly women. The group have succeeded in increasing human bone formation to such an extent that it will mark a decisive improvement in the quality of life for most osteoporosis sufferers.
Human bone tissue dies and is recreated constantly. Roughly one-tenth of our bone substance is in a continuous state of flux, in which osteoclasts or “bone-destroying cells” wage a battle with osteoblasts that form new bone using calcium. Generally this process is in balance, such that the amount of bone remains constant. However, weakening of the bones through calcium loss, known as osteoporosis, has become a major health issue, particularly among older women. The onset of the disease stems from the continued activity of osteoclasts while their counterparts the osteoblasts no longer function as efficiently as before.
The Stockholm-based research team under Prof. Rolf Sveiby has managed to apply gene technology to construct a hormone compound that revives the osteoblasts and stimulates their activity. The treatment has not only proved effective in medical trials, it is also relatively cheap. The Karolina Institute comments in its press release that the team has involved scientist from all over Scandinavia and from Germany. A spokesman for the Swedish Ministry of Health also observed that the discovery will bring savings in osteoporosis treatment costs of the order of several thousand million Euros in Sweden alone, quite apart from the reductions in human suffering that the treatment can be expected to produce. The Ministry statement goes on to say that while the breakthrough may not qualify the research team for a Nobel Prize, it is certain to receive many other international awards for the work carried out so far.
Toteuma-arvio 2026
Toteuma lyhyesti
- Ilmiön toteuma: 5/5
- Toteuma viiden vuoden tarkkuudella: kyllä; arviointi-ikkuna on 1996–2006
- Toteuma väljemmällä aikahorisontilla: kyllä, erittäin vahvasti
- Ilmiön ydin: osteoporoosia hoidetaan lääkkeellä, joka aktivoi uuden luun muodostumista eikä vain hidasta luukatoa.
Ensimmäinen luun muodostusta stimuloiva osteoporoosilääke teriparatidi hyväksyttiin vuonna 2002. Hoito kohdistuu juuri osteoblastien toimintaan, joten sekä biologinen periaate että ajoitus osuivat hyvin.
Johtopäätös: ennuste toteutui poikkeuksellisen täsmällisesti ydinilmiön ja ajoituksen osalta.